Eif4a/pdcd4 pathway, a factor for doxorubicin chemoresistance in a triple-negative breast cancer cell model

HIGHLIGHTS

  • who: Alina Gonzu00e1lez-Ortiz and collaborators from the Departamento de Bioquu00edmica, Facultad de Medicina Mexicali, Universidad Autu00f3noma de Baja California, Mexicali, Mexico have published the article: eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model, in the Journal: Cells employ several adaptive mechanisms under conditions of accelerated cell division,
  • what: More importantly, the chemoresistance of variant B in the study confirmed that novel therapeutic approaches can be developed based on the regulation of protein translation initiation factors.
  • how: Critically this result was consistent with the expression . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?